Federal Register / Vol. 72, No. 115 / Friday, June 15, 2007 / Notices 33235 

section 2119 of the Act, 42 U.S.C. 

300aa–19, as added by Public Law 99–

660 and amended, HRSA is requesting 

nominations for three voting members 

of the ACCV. 

The ACCV advises the Secretary on 

the implementation of the VICP. The 

activities of the ACCV include: 

recommending changes in the Vaccine 

Injury Table at its own initiative or as 

the result of the filing of a petition; 

advising the Secretary in implementing 

section 2127 regarding the need for 

childhood vaccination products that 

result in fewer or no significant adverse 

reactions; surveying Federal, State, and 

local programs and activities related to 

gathering information on injuries 

associated with the administration of 

childhood vaccines, including the 

adverse reaction reporting requirements 

of section 2125(b); advising the 

Secretary on the methods of obtaining, 

compiling, publishing, and using 

credible data related to the frequency 

and severity of adverse reactions 

associated with childhood vaccines; and 

recommending to the Director of the 

National Vaccine Program that vaccine 

safety research be conducted on various 

vaccine injuries. 

The ACCV consists of nine voting 

members appointed by the Secretary as 

follows: (1) Three health professionals, 

who are not employees of the United 

States Government and have expertise 

in the health care of children, and the 

epidemiology, etiology, and prevention 

of childhood diseases, and the adverse 

reactions associated with vaccines, at 

least two shall be pediatricians; (2) three 

members from the general public, at 

least two shall be legal representatives 

(parents or guardians) of children who 

have suffered a vaccine-related injury or 

death; and (3) three attorneys, at least 

one shall be an attorney whose specialty 

includes representation of persons who 

have suffered a vaccine-related injury or 

death, and one shall be an attorney 

whose specialty includes representation 

of vaccine manufacturers. In addition, 

the Director of the National Institutes of 

Health, the Assistant Secretary for 

Health, the Director of the Centers for 

Disease Control and Prevention, and the 

Commissioner of the Food and Drug 

Administration (or the designees of such 

officials) serve as nonvoting ex officio 

members. 

Specifically, HRSA is requesting 

nominations for three voting members 

of the ACCV representing: (1) A 

pediatrician who has expertise in the 

health care of children, the 

epidemiology, etiology, and prevention 

of childhood diseases, and the adverse 

reactions associated with vaccines; (2) a 

member of the general public who is the 

legal representative of a child who has 

suffered a vaccine injury or death; and 

(3) an attorney whose specialty includes 

representation of persons who have 

suffered vaccine injuries or deaths. 

Nominees will be invited to serve a 3- 

year term beginning January 1, 2008, 

and ending December 31, 2010. 

Interested persons may nominate one 

or more qualified persons for 

membership on the ACCV. Nominations 

shall state that the nominee is willing to 

serve as a member of the ACCV and 

appears to have no conflict of interest 

that would preclude the ACCV 

membership. Potential candidates will 

be asked to provide detailed information 

concerning consultancies, research 

grants, or contracts to permit evaluation 

of possible sources of conflicts of 

interest. A curriculum vitae or resume 

should be submitted with the 

nomination. 

The Department of Health and Human 

Services has special interest in assuring 

that women, minority groups, and the 

physically disabled are adequately 

represented on advisory committees; 

and therefore, extends particular 

encouragement to nominations for 

appropriately qualified female, 

minority, or disabled candidates. 

Dated: June 11, 2007. 

Caroline Lewis, 

Associate Administrator for Management. 

[FR Doc. E7–11548 Filed 6–14–07; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Meeting: Secretary’s 

Advisory Committee on Genetics, 

Health, and Society 

Pursuant to Public Law 92–463, 

notice is hereby given of the thirteenth 

meeting of the Secretary’s Advisory 

Committee on Genetics, Health, and 

Society (SACGHS), U.S. Public Health 

Service. The meeting will be held from 

on Tuesday, July 10, 2007, from 8:30 

a.m. to approximately 5 p.m. in Room 

800 of the Hubert H. Humphrey 

Building, 200 Independence Avenue, 

SW., Washington, DC 20001. The 

meeting will be open to the public with 

attendance limited to space available. 

The meeting also will be Web cast. 

The meeting will focus primarily on 

the issue of gene patents and licensing 

practices and consist of a series of 

presentations and discussions involving 

international experts on how other 

countries are addressing questions 

related to the impact of gene patents and 

licensing practices on patient access to 

genetic tests. In addition, the SACGHS 

task force on oversight of genetic testing 

will present a brief report on the 

progress of its fact-finding and 

consultative efforts with regard to the 

Secretary’s charge. The Committee will 

also be updated about the public 

comments received in response to the 

Committee’s solicitation on its draft 

report on pharmacogenomics. 

Time will be provided for public 

comments. The Committee would 

welcome hearing from anyone wishing 

to provide public comment on any issue 

related to genetics, health, and society. 

Individuals who would like to provide 

public comment should notify the 

SACGHS Executive Secretary, Ms. Sarah 

Carr, by telephone at 301–496–9838 or 

e-mail at carrs@od.nih.gov. The 

SACGHS office is located at 6705 

Rockledge Drive, Suite 750, Bethesda, 

MD 20892. Anyone planning to attend 

the meeting who is in need of special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, is also asked to 

contact the Executive Secretary. 

Under authority of 42 U.S.C. 217a, 

Section 222 of the Public Health Service 

Act, as amended, the Department of 

Health and Human Services established 

SACGHS to serve as a public forum for 

deliberations on the broad range of 

human health and societal issues raised 

by the development and use of genetic 

and genomic technologies and, as 

warranted, to provide advice on these 

issues. The draft meeting agenda and 

other information about SACGHS, 

including information about access to 

the Web cast, will be available at the 

following Web site: http:// 

www4.od.nih.gov/oba/sacghs.htm. 

Dated: June 7, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2964 Filed 6–14–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine, Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 


jlentini on PROD1PC65 with NOTICES